Recombinant Mouse Glypican 2/GPC2 Protein
Beta LifeScience
SKU/CAT #: BLK-02044P-100UG
Mouse Glypican 2/GPC2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Mouse Glypican 2/GPC2 Protein
Beta LifeScience
SKU/CAT #: BLK-02044P-100UG
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Mouse Glypican 2/GPC2 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains His22-Ser556. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q8BKV1 |
Target Symbol | Glypican 2/GPC2 |
Synonyms | Glypican-2; 2410016G05Rik; Cerebroglycan; GPC2 |
Species | Mouse |
Expression System | HEK293 |
Tag | C-His |
Expression Range | His22-Ser556 |
Mol. Weight | The protein has a predicted MW of 59.9 kDa. Due to autocatalytic cleavage, the protein migrates to 32-35 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Glypicans can function as coreceptors for multiple signaling molecules known for regulating cell growth, motility, and differentiation. Some members of the glypican family, including glypican 2 (GPC2) and glypican 3 (GPC3), are expressed in childhood cancers and liver cancers, respectively. Antibody-based therapies targeting glypicans are being investigated in preclinical and clinical studies, with the goal of treating solid tumors that do not respond to standard therapies. |